A mouse to dog to human cross-species drug discovery pipeline to treat cancer

Purpose

Virginia Tech is participating in a clinical research project by the Duke Cancer Institute at Duke University for dogs with osteosarcoma. This study will use patient-derived models of cancer from dogs and humans to identify new therapies to treat cancers that affect both species, with a particular focus on sarcomas.

Eligibility

Dogs with newly diagnosed appendicular osteosarcoma who have not received prior treatment for their osteosarcoma.

Exclusion

  • Diagnosis of any immune-mediated disease, e.g. IBD, IMHA.
  • Diagnosis of uncontrolled allergic disease or hypersensitivities.
  • Current use of immunosuppressives such as prednisone, Apoquel, any immunosuppressive treatment for IBD, IMHA, IMTP, IMPA.
  • Current or recent (within past 3 weeks) history of chemotherapy treatment.
  • Evidence of metastatic disease.
  • Concurrent diagnosis of another tumor type.

Study Design

Dogs will undergo surgery to remove their tumor. Following removal, a sample from the tumor will be shipped to Duke Cancer Institute at Duke University, where it will be processed to help develop the patient-derived models of cancer. Since the sample is taken after the tumor is surgically removed, participation in the study will not affect the course of your dog’s treatment.

Compensation

There is no compensation for participation, but we hope the information gained in this study will improve diagnosis and treatment of future pets and humans with osteosarcoma.

Contact

Dr. Joanne Tuohy, Surgical Oncology
Phone: 540-231-4621 | Email: jltuohy@vt.edu

Mindy Quigley, Clinical Trials Coordinator
Office Phone: 540-231-1363 | Email: mindyq@vt.edu

If your query is urgent, please call the Small Animal Hospital on 540-231-4621.